FDA's Generic Drug Workload, Productivity Beating Budget Estimates

22 Feb 2016

ANDA submissions and approvals for FY 2017 likely to be higher than agency estimates, but FDA also predicts improved median approval time.

FDA expectations for the next fiscal year of ANDA approvals and submissions appear to be underestimated.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Already a subscriber?